Neuronetics, Inc. (STIM) Q1 2022 Earnings Call Transcript
STIM earnings call for the period ending March 31, 2022.
Stay updated with breaking news from Neuronetics Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
STIM earnings call for the period ending March 31, 2022.
AtriCure (NASDAQ:ATRC – Get Rating) and Neuronetics (NASDAQ:STIM – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Institutional and Insider Ownership 93.3% of AtriCure shares are owned by institutional […]
Shares of Neuronetics, Inc. (NASDAQ:STIM – Get Rating) have been assigned an average recommendation of “Hold” from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price target among […]
Neuronetics, Inc. (NASDAQ:STIM – Get Rating) major shareholder Cannell Capital Llc purchased 25,000 shares of the business’s stock in a transaction on Monday, April 11th. The stock was bought at an average cost of $2.95 per share, for a total transaction of $73,750.00. Following the purchase, the insider now owns 3,021,594 shares of the company’s […]
Neuronetics, Inc. (NASDAQ:STIM – Get Rating) major shareholder Cannell Capital Llc acquired 33,400 shares of the company’s stock in a transaction dated Wednesday, April 13th. The shares were acquired at an average cost of $2.88 per share, with a total value of $96,192.00. Following the completion of the purchase, the insider now owns 3,130,913 shares […]